Examining the link between fatty liver disease and kidney inflammation in adults

Assessment of the Association Between Metabolic Associated Fatty Liver Disease MFLD and Glomerulonephritis

Observational Assiut University · NCT06157125

This study looks at whether adults with kidney inflammation also have fatty liver disease and what factors might link the two conditions.

Quick facts

Study typeObservational
Enrollment100 (estimated)
Ages19 Years to 80 Years
SexAll
SponsorAssiut University Academic / other
Locations2 sites (Asyut and 1 other locations)
Trial IDNCT06157125 on ClinicalTrials.gov

What this trial studies

This observational study aims to assess the prevalence of Metabolic Associated Fatty Liver Disease (MFLD) in patients over 18 years old who have been diagnosed with biopsy-proven primary glomerulonephritis. The study will evaluate the association between these two conditions, considering factors such as obesity and metabolic syndrome that may contribute to the development of fatty liver disease in this population. By analyzing patient data, the study seeks to identify potential risk factors and improve understanding of the relationship between kidney and liver health.

Who should consider this trial

Good fit: Ideal candidates for this study are adults over 18 years old with biopsy-proven primary glomerulonephritis.

Not a fit: Patients with secondary glomerulonephritis, significant obesity, diabetes, or other specified exclusions may not benefit from this study.

Why it matters

Potential benefit: If successful, this study could lead to better management strategies for patients with glomerulonephritis, potentially reducing the risk of fatty liver disease.

How similar studies have performed: While there is existing literature on the relationship between metabolic syndrome and kidney disease, this specific association has not been extensively studied, making it a novel approach.

Eligibility criteria

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Patients with biopsy proven primary glomerulonephritis.
* Age \>18 years

Exclusion Criteria:

1. Patients with e-GFR\<60ml/min/1.73m2
2. Patients with secondary glomerulonephritis
3. Patients with body mass index \>35 kg/m2
4. Patients known to be diabetic.
5. Patients known to be hypertensive.
6. Patients with HCV or HBV infection either acute or chronic
7. Patients with acute hepatitis whatever the aetiology
8. Patients with autoimmune diseases

Where this trial is running

Asyut and 1 other locations

How to participate

  1. Review the eligibility criteria above with your treating physician.
  2. Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
  3. Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions Assessment of Patients With Biopsy Proven Primary Glomerulonephritis Above 18 Years of Age for MFLD Development
Last reviewed 2026-06-13 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.